• In late April 2026, Nuvalent announced a multi-year collaboration with Guardant Health to use Guardant’s Infinity tissue and liquid biopsy platform to support clinical development, potential companion diagnostics, and future global commercialization of Nuvalent’s oncology pipeline.
• This partnership reinforces how precision diagnostics are becoming integral to drug development, tying Guardant’s testing capabilities directly to emerging targeted cancer therapies and potential regulatory pathways.
• We’ll now examine how this Nuvalent collaboration, particularly its companion diagnostic potential, could influence Guardant Health’s broader investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Guardant Health Investment Narrative Recap

To be a shareholder in Guardant Health, you need to believe that blood and tissue based cancer diagnostics can scale into a large, durable business despite ongoing losses and heavy investment in Shield and Reveal. The Nuvalent deal arguably supports the near term catalyst of deeper pharma integration and companion diagnostic traction, but it does little to reduce the key risk around sustained cash burn, potential dilution, and the challenge of reaching cash flow breakeven on schedule.

Among recent developments, the multi year Nuvalent collaboration stands out because it directly ties Guardant Infinity to a growing oncology pipeline, echoing prior partnerships with Merck and Pfizer. If these companion diagnostic efforts translate into more embedded roles in drug development and, eventually, approved tests, they could reinforce the biopharma and data segment as an important complement to Guardant’s screening and MRD growth engines.

Yet in contrast to these opportunities, investors should also be aware of the risk that persistent cash burn and rising operating expenses could...

Guardant Health's narrative projects $2.1 billion revenue and $105.5 million earnings by 2029.

Uncover how Guardant Health's forecasts yield a $128.33 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$2.3 billion of revenue and positive earnings by 2028, but this new Nuvalent collaboration could either reinforce or challenge those bullish expectations depending on how you weigh companion diagnostic growth against the added execution risks they highlight.

Explore 5 other fair value estimates on Guardant Health - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Guardant Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Guardant Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Guardant Health's overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.